Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 104
Filter
1.
Br J Surg ; 108(12): 1465-1473, 2021 12 01.
Article in English | MEDLINE | ID: mdl-34636842

ABSTRACT

BACKGROUND: The St Gallen 2019 guidelines for primary therapy of early breast cancer recommend omission of completion axillary lymph node dissection (cALND), regardless of histological type, in patients with one or two sentinel lymph node (SLN) metastases. Concurrently, adjuvant chemotherapy is endorsed for luminal A-like disease with four or more axillary lymph node (ALN) metastases. The aim of this study was to estimate the proportion of patients with invasive lobular cancer (ILC) versus invasive ductal cancer of no special type (NST) with one or two SLN metastases for whom cALND would have led to a recommendation for adjuvant chemotherapy. METHODS: Patients with ILC and NST who had surgery between 2014 and 2017 were identified in the National Breast Cancer Register of Sweden. After exclusion of patients with incongruent or missing data, those who fulfilled the St Gallen 2019 criteria for cALND omission were included in the population-based study cohort. RESULTS: Some 1886 patients in total were included in the study, 329 with ILC and 1507 with NST. Patients with ILC had a higher metastatic nodal burden and were more likely to have a luminal A-like subtype than those with NST. The prevalence of at least four ALN metastases was higher in ILC (31.0 per cent) than NST (14.9 per cent), corresponding to an adjusted odds ratio of 2.26 (95 per cent c.i. 1.59 to 3.21). Luminal A-like breast cancers with four or more ALN metastases were over-represented in ILC compared with NST, 52 of 281 (18.5 per cent) versus 43 of 1299 (3.3 per cent) (P < 0.001). CONCLUSION: Patients with ILC more often have luminal A-like breast cancer with at least four nodal metastases. Omission of cALND in patients with luminal A-like invasive lobular cancer and one or two SLN metastases warrants future attention as there is a risk of nodal understaging and undertreatment in one-fifth of patients.


Nowadays patients who have breast cancer with one to two metastases in the first draining axillary lymph nodes are not recommended to undergo completion surgery of the axilla if they have breast-conserving surgery and will have adequate postoperative oncological treatment. Lobular breast cancer is the second most common type of breast cancer, and this study shows that patients with this type have an increased risk of having lymph node metastases remaining if completion surgery is omitted. The diagnosis of additional lymph node metastases is importance for guidance regarding adjuvant oncological therapy in lobular cancer with a hormonally sensitive low proliferative subtype.


Subject(s)
Breast Neoplasms/pathology , Carcinoma, Lobular/pathology , Lymphatic Metastasis , Sentinel Lymph Node/pathology , Axilla , Carcinoma, Ductal, Breast/pathology , Female , Humans , Middle Aged , Neoplasm Staging , Practice Guidelines as Topic
2.
Br J Dermatol ; 184(1): 60-67, 2021 01.
Article in English | MEDLINE | ID: mdl-32133615

ABSTRACT

BACKGROUND: The incidence of cutaneous malignant melanoma (CMM) continues to increase in most countries worldwide and the majority are diagnosed with thin tumours (≤ 1 mm). OBJECTIVES: The aim of the present study was to investigate the melanoma-specific survival (MSS) as well as conditional MSS (CMSS) in patients with thin CMM in Sweden. PATIENTS AND METHODS: Clinical and histological parameters were obtained from the Swedish Melanoma Registry for patients diagnosed with thin CMM between 1990 and 2017. Patients were followed until the end of 2017. MSS as well as CMSS for different thickness groups were calculated using the Kaplan-Meier method and Cox regression analyses were used to calculate for survival differences between thickness groups. RESULTS: There were 31 670 patients included for final analyses. The overall 10- and 20-year MSS for thin CMMs was 97% [95% confidence interval (CI) 97-97] and 95% (95% CI 95-96), respectively. From 0·7 mm and above, MSS decreased significantly with increasing thickness level. All thickness groups had an increased survival over time. The lowest CMSS was confirmed for men with 1·0 mm in thickness but their 10-year CMSS increased steadily over time. Women had overall better MSS as well as CMSS than men. However, the relation between MSS and CMSS was similar for both sexes. CONCLUSIONS: MSS was confirmed as excellent for patients with thin CMMs in Sweden. Although we could show a decreased MSS for patients with 0·7 mm thickness and above, the long-term survival and, in addition, a very favourable CMSS for those patients do not support more extended follow-up programmes than the current recommendations in Sweden.


Subject(s)
Melanoma , Skin Neoplasms , Female , Humans , Incidence , Male , Melanoma/epidemiology , Prognosis , Registries , Skin Neoplasms/epidemiology , Sweden/epidemiology
3.
Br J Surg ; 107(10): 1299-1306, 2020 09.
Article in English | MEDLINE | ID: mdl-32335901

ABSTRACT

BACKGROUND: The implementation of screening programmes in Sweden during the mid-1990s increased the number of small node-negative breast cancers. In this era before staging by sentinel node biopsy, routine axillary dissection for staging of early breast cancer was questioned owing to the increased morbidity and lack of perceived benefit. The long-term risk of axillary recurrence when axillary staging is omitted remains unclear. METHODS: This prospective observational multicentre cohort study included Swedish women diagnosed with breast cancer between 1997 and 2002. The patients had clinically node-negative, pT1a-b, grade I-II tumours. No axillary staging or dissection was performed. The primary outcome was ipsilateral axillary recurrence and survival. RESULTS: A total of 1543 patients were included. Breast-conserving surgery (BCS) was performed in 94·0 per cent and the rest underwent mastectomy. After surgery, 58·1 per cent of the women received adjuvant radiotherapy, 11·9 per cent adjuvant endocrine therapy and 31·5 per cent did not receive any adjuvant treatment. After a median follow-up of 15·5 years, 6·4 per cent developed contralateral breast cancer and 16·5 per cent experienced a recurrence. The first recurrence was local in 116, regional in 47 and distant in 59 patients. The breast cancer-specific survival rate was 93·7 per cent after 15 years. There were no differences in overall or breast cancer-specific survival between patients who received adjuvant radiotherapy and those who did not. Only 3·0 per cent of patients had an axillary recurrence, which was isolated in only 1·0 per cent. CONCLUSION: Axillary surgery can safely be omitted in patients with low-grade, T1a-b, cN0 breast cancers. This large prospective cohort with 15-year follow-up had a very low incidence of axillary recurrences and high breast cancer-specific survival rate.


ANTECEDENTES: La puesta en marcha en Suecia, a mediados de los años 90, de los programas de cribaje aumentó el número de cánceres de mama precoces con ganglios negativos. En esa era, antes de la estadificación mediante la biopsia del ganglio centinela, se cuestionó la disección axilar rutinaria para la estadificación del cáncer de mama precoz debido a su aumento de la morbilidad y la falta de percepción de beneficio. El riesgo de recidiva axilar a largo plazo cuando no se omite la estadificación axilar sigue sin estar claro. MÉTODOS: Estudio de cohortes prospectivo, observacional y multicéntrico de las mujeres suecas diagnosticadas de cáncer de mama entre 1997-2002. Se incluyeron las pacientes con ganglios clínicamente no detectables, pT1a-b, grados I-II y no se realizó disección/estadificación axilar en ninguna de ellas. El resultado principal fue la recidiva axilar ipsilateral y la supervivencia. RESULTADOS: Se incluyeron 1.543 pacientes. Se realizó cirugía conservadora de la mama (breast conserving surgery, BCS) en el 94% de las mujeres y en las restantes se practicó una mastectomía. Tras la BCS, el 58% de las mujeres recibió radioterapia adyuvante, el 12% tratamiento endocrino adyuvante y el 32% no recibió ningún tratamiento adyuvante. Tras una mediana de seguimiento de 15,5 años, el 6% desarrolló un cáncer de mama contralateral y un 14% una recidiva. La primera recidiva fue local en 116 pacientes, regional en 47 y a distancia en 59. La supervivencia específica para el cáncer de mama a los 15 años fue del 94%. No hubo diferencias en la supervivencia general o específica por cáncer de mama entre las pacientes que recibieron radioterapia adyuvante y las que no. Solo el 3% de las pacientes presentó una recidiva axilar, de las cuales tan solo el 1% padecieron exclusivamente una recidiva axilar. CONCLUSIÓN: La cirugía axilar se puede omitir con seguridad en los cánceres de mama de bajo grado, T1a-b, cN0. Esta gran cohorte prospectiva con un seguimiento de 15 años muestra que la incidencia de recidivas axilares es muy baja y la supervivencia específica por cáncer de mama muy alta.


Subject(s)
Breast Neoplasms/pathology , Breast Neoplasms/surgery , Adult , Aged , Aged, 80 and over , Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/mortality , Female , Follow-Up Studies , Humans , Mastectomy, Segmental , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Prospective Studies , Radiotherapy, Adjuvant/statistics & numerical data , Sweden/epidemiology , Tamoxifen/therapeutic use
4.
J Eur Acad Dermatol Venereol ; 31(9): 1468-1474, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28419674

ABSTRACT

BACKGROUND: Prognostic factors in patients with localized primary cutaneous malignant melanoma (CMM) are well described. However, prognostic factors for recurrence are less documented. OBJECTIVES: The aim of this study was to identify prognostic risk factors for first recurrence in patients with localized stages I-II CMM using population-based data. METHODS: This study included 1437 CMM patients registered in one region of Sweden during 1999-2012 follow-up through 31 December 2012. To identify first recurrence of CMM disease, data from a care data warehouse, the pathology and radiology department registries were used. Patients were also followed through a census register and the national Cause of Death Register. RESULTS: The 5- and 10-year recurrence-free survival (RFS) were 85.7% and 81.2%, respectively. The most common site of first recurrence was regional lymph node metastasis closely followed by distant metastasis. After adjusting for all prognostic factors, women had 50% lower risk of recurrence than men (HR = 0.5, 95% CI 0.4-0.7) and patients ≥70 had higher risk compared to patients 55-69 years (HR = 1.7, 95% CI 1.2-2.5). Other significant prognostic factors for risk of recurrence were tumour thickness, presence of ulceration, Clark's level of invasion and histogenetic type. CONCLUSION: Tumour thickness was found to be the predominant risk factor for recurrence. The prognostic factors for recurrence coincided with prognostic factors for CMM death. The most common site of first recurrence in stages I-II CMM is regional lymph node (42.8%) closely followed by distant metastases (37.6%), a fact which has to be taken into consideration when choosing follow-up strategies.


Subject(s)
Melanoma/pathology , Neoplasm Recurrence, Local , Registries , Skin Neoplasms/pathology , Aged , Disease-Free Survival , Female , Humans , Male , Melanoma/epidemiology , Middle Aged , Prognosis , Recurrence , Risk Factors , Skin Neoplasms/epidemiology , Sweden/epidemiology
5.
Eur J Cancer ; 59: 171-178, 2016 05.
Article in English | MEDLINE | ID: mdl-27046697

ABSTRACT

BACKGROUND: Several major analyses have identified a consistent set of independent risk factors for cutaneous malignant melanoma (CMM). A few prognostic models have been presented but some are based on a limited number of patients and others are based on selected groups of patients referred to major institutions. No nationwide population-based prognostic instrument for survival of CMM has been presented. The Swedish Melanoma Register (SMR) database covers 99% of CMM diagnosed in Sweden and includes today >50,000 cases. OBJECTIVES: To create a prognostic instrument based on SMR data to give highly reliable risk profiles for patients diagnosed with localised CMM. METHODS: Clinicopathological data were linked to the cause of death registry for calculation of CMM-specific survival. A generalised gamma method was used to derive 1, 5 and 10year probabilities of death for each combination of patient and tumour data: age, sex, tumour site, tumour thickness, tumour ulceration, Clark's level of invasion and when applicable also outcome of sentinel node biopsy (SNB). RESULTS: Tumour thickness had the highest prognostic impact, explaining 77% of the model. Women had 30% lower risk of death because of CMM than men. Presence of ulceration nearly doubled the risk. If the patient had a positive SNB status the risk of death due to CMM increased three times versus a negative SNB status. CONCLUSION: This unique population-based prognostic model for primary CMM shows better survival than the American Joint Commission on Cancer prognostic model widely used. The reason is probably that the referral bias is eliminated in a population-based cohort.


Subject(s)
Melanoma/mortality , Skin Neoplasms/mortality , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Humans , Male , Middle Aged , Prognosis , Registries , Sweden/epidemiology , Young Adult
6.
J Intern Med ; 280(4): 375-87, 2016 10.
Article in English | MEDLINE | ID: mdl-26992108

ABSTRACT

OBJECTIVE: Women with active sunlight exposure habits experience a lower mortality rate than women who avoid sun exposure; however, they are at an increased risk of skin cancer. We aimed to explore the differences in main causes of death according to sun exposure. METHODS: We assessed the differences in sun exposure as a risk factor for all-cause mortality in a competing risk scenario for 29 518 Swedish women in a prospective 20-year follow-up of the Melanoma in Southern Sweden (MISS) cohort. Women were recruited from 1990 to 1992 (aged 25-64 years at the start of the study). We obtained detailed information at baseline on sun exposure habits and potential confounders. The data were analysed using modern survival statistics. RESULTS: Women with active sun exposure habits were mainly at a lower risk of cardiovascular disease (CVD) and noncancer/non-CVD death as compared to those who avoided sun exposure. As a result of their increased survival, the relative contribution of cancer death increased in these women. Nonsmokers who avoided sun exposure had a life expectancy similar to smokers in the highest sun exposure group, indicating that avoidance of sun exposure is a risk factor for death of a similar magnitude as smoking. Compared to the highest sun exposure group, life expectancy of avoiders of sun exposure was reduced by 0.6-2.1 years. CONCLUSION: The longer life expectancy amongst women with active sun exposure habits was related to a decrease in CVD and noncancer/non-CVD mortality, causing the relative contribution of death due to cancer to increase.


Subject(s)
Cause of Death , Sunlight , Adult , Cardiovascular Diseases/mortality , Environmental Exposure/adverse effects , Female , Follow-Up Studies , Humans , Life Expectancy , Melanoma/prevention & control , Middle Aged , Neoplasms/mortality , Risk Factors , Skin Neoplasms/prevention & control , Sunlight/adverse effects , Sweden
7.
Br J Dermatol ; 172(3): 700-6, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25323770

ABSTRACT

BACKGROUND: Both patient survival and the proportion of patients diagnosed with thin cutaneous malignant melanoma (CMM) have been steadily rising in Sweden as in most Western countries, although the rate of improvement in survival appears to have declined in Sweden at the end of the last millennium. OBJECTIVES: To analyse the most recent trends in the distribution of tumour thickness (T category) as well as CMM-specific survival in Swedish patients diagnosed during 1997-2011. METHODS: This nationwide population-based study included 30,590 patients registered in the Swedish Melanoma Register (SMR) and diagnosed with a first primary invasive CMM during 1997-2011. The patients were followed through 2012 in the national Cause of Death Register. RESULTS: Logistic and Cox regression analyses adjusting for age at diagnosis, tumour site and healthcare region were carried out. The odds ratio for being diagnosed with thicker tumours was significantly reduced (P < 0·001) and the CMM-specific survival significantly improved in men diagnosed during 2007-2011 compared with men diagnosed during 1997-2001 (hazard ratio = 0·81; 95% confidence interval 0·72-0·91; P < 0·001), while the corresponding differences for women were not significant. Women were diagnosed with significantly thicker tumours during 2002-2006 and a tendency towards decreased survival was observed compared with those diagnosed earlier (during 1997-2001) and later (during 2007-2011). CONCLUSIONS: In Sweden, the CMMs of men are detected earlier over time and this seems to be followed by an improved CMM-specific survival for men. Women are still diagnosed with considerably thinner tumours and they experience a better survival than men.


Subject(s)
Melanoma/mortality , Skin Neoplasms/mortality , Adult , Age Distribution , Aged , Aged, 80 and over , Female , Humans , Incidence , Kaplan-Meier Estimate , Male , Melanoma/pathology , Middle Aged , Mortality/trends , Skin Neoplasms/pathology , Sweden/epidemiology , Melanoma, Cutaneous Malignant
8.
J Intern Med ; 276(1): 77-86, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24697969

ABSTRACT

BACKGROUND: Sunlight exposure and fair skin are major determinants of human vitamin D production, but they are also risk factors for cutaneous malignant melanoma (MM). There is epidemiological evidence that all-cause mortality is related to low vitamin D levels. METHODS: We assessed the avoidance of sun exposure as a risk factor for all-cause mortality for 29 518 Swedish women in a prospective 20-year follow-up of the Melanoma in Southern Sweden (MISS) cohort. Women were recruited from 1990 to 1992 and were aged 25 to 64 years at the start of the study. We obtained detailed information at baseline on their sun exposure habits and potential confounders. Multivariable flexible parametric survival analysis was applied to the data. RESULTS: There were 2545 deaths amongst the 29 518 women who responded to the initial questionnaire. We found that all-cause mortality was inversely related to sun exposure habits. The mortality rate amongst avoiders of sun exposure was approximately twofold higher compared with the highest sun exposure group, resulting in excess mortality with a population attributable risk of 3%. CONCLUSION: The results of this study provide observational evidence that avoiding sun exposure is a risk factor for all-cause mortality. Following sun exposure advice that is very restrictive in countries with low solar intensity might in fact be harmful to women's health.


Subject(s)
Cause of Death , Environmental Exposure , Sunbathing , Sunlight , Adult , Environmental Exposure/adverse effects , Environmental Exposure/statistics & numerical data , Female , Humans , Melanoma/etiology , Melanoma/mortality , Middle Aged , Prospective Studies , Risk Factors , Risk Reduction Behavior , Skin Neoplasms/etiology , Skin Neoplasms/mortality , Socioeconomic Factors , Sunbathing/psychology , Sunbathing/statistics & numerical data , Sunlight/adverse effects , Sweden/epidemiology , Vitamin D/metabolism
9.
Br J Dermatol ; 169(5): 1049-55, 2013 Nov.
Article in English | MEDLINE | ID: mdl-23855428

ABSTRACT

BACKGROUND: BRAF and NRAS mutations are frequently found in melanoma tumours, and recently developed BRAF-targeted therapies demonstrate significant clinical benefit. OBJECTIVES: We sought to investigate the clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. METHODS: In total, 237 tumours, mostly metastatic lesions, from 203 patients were screened for mutations in exon 15 of BRAF and exon 2 of NRAS using Sanger sequencing. BRAF and NRAS mutation status was analysed in relation to clinical and histopathological characteristics, and outcome. RESULTS: Mutation in BRAF and NRAS was present in 43% (88% V600E, 10% V600K) and 30% (48% Q61K, 40% Q61R) of metastatic melanomas, respectively. We found consistent BRAF and NRAS mutation status in all but one of 27 patients with multiple metastases. BRAF mutation was associated with younger age at primary diagnosis (P = 0.02). Among patients with distant metastatic melanoma, patients with BRAF-mutant tumours without BRAF inhibitor treatment had inferior survival compared with patients with BRAF inhibitor treatment [hazard ratio (HR) 2.35, 95% confidence interval (CI) 1.10-5.01, P = 0.03]. We also observed a trend towards better prognosis for patients with wild-type and NRAS-mutant tumours compared with BRAF V600E-mutant tumours (HR 0.64, 95% CI 0.39-1.04, P = 0.07; and HR 0.76, 95% CI 0.48-1.21, P = 0.25, respectively). CONCLUSIONS: We were able to confirm the effect of BRAF inhibitor treatment in a single clinical institution. The results suggest further that BRAF mutation is a weak prognostic factor but a strong predictive factor and that BRAF-mutant melanoma might constitute one or more distinct subtypes of the disease with certain aetiology and clinical outcome.


Subject(s)
GTP Phosphohydrolases/genetics , Genes, ras , Melanoma/genetics , Membrane Proteins/genetics , Mutation , Proto-Oncogene Proteins B-raf/genetics , Skin Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Disease-Free Survival , Exons , Female , Humans , Indoles/therapeutic use , Male , Melanoma/drug therapy , Melanoma/surgery , Middle Aged , Neoplasm Metastasis , Neoplasm Recurrence, Local/genetics , Prognosis , Proto-Oncogene Proteins B-raf/antagonists & inhibitors , Skin Neoplasms/drug therapy , Skin Neoplasms/surgery , Sulfonamides/therapeutic use , Vemurafenib
10.
Eur J Cancer ; 49(12): 2705-16, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23583439

ABSTRACT

BACKGROUND: A worse outcome has been reported for cutaneous malignant melanoma (CMM) patients with low socioeconomic status. We have investigated the association between level of education, clinical stage at diagnosis (stage at diagnosis) and CMM-specific survival in Sweden. METHODS: We identified 27,235 patients from the Swedish Melanoma Register diagnosed with a primary invasive CMM between 1990 and 2007 and linked data to nationwide, population-based, health and census registers with a follow-up to 2010. RESULTS: The odds ratio (OR) of higher disease stage at diagnosis was significantly increased in lower education groups (OR stage II versus I=1.6; 95% confidence interval (CI)=1.5-1.7. OR stage III-IV versus I=2.3; 95% CI=1.8-2.9). The risk of dying of CMM, was significantly increased in patients with low (hazard ratio (HR) low versus high=2.02; 95% CI=1.80-2.26; p<0.0001) and intermediate (HR intermediate versus high=1.35; 95% CI=1.20-1.51; p<0.0001) level of education. After adjustment for age, gender, stage at diagnosis and other known prognostic factors, the HRs remained significant for low versus high (HR=1.13; 95% CI=1.01-1.27; p=0.04) but not for intermediate versus high (HR=1.11; 95% CI=0.99-1.24; p=0.08) education. The HR associated with low level of education was significantly higher among female patients, patients <55 years, patients with truncal tumours and during the first 5 years after diagnosis. CONCLUSION: Lower level of education is associated with reduced CMM-specific survival, which may at least partially be attributed to a more advanced stage at diagnosis. These results emphasise the need for improved early detection strategies.


Subject(s)
Educational Status , Melanoma/diagnosis , Skin Neoplasms/diagnosis , Skin/pathology , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Incidence , Kaplan-Meier Estimate , Logistic Models , Male , Melanoma/epidemiology , Melanoma/surgery , Middle Aged , Neoplasm Staging , Outcome Assessment, Health Care/statistics & numerical data , Prognosis , Proportional Hazards Models , Registries/statistics & numerical data , Skin Neoplasms/epidemiology , Skin Neoplasms/surgery , Social Class , Sweden/epidemiology
11.
Eur J Surg Oncol ; 39(6): 601-7, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23579175

ABSTRACT

BACKGROUND: The need for completion axillary lymph node dissection (ALND) in breast cancer patients with micrometastases in the sentinel nodes (SNs) is controversial. The aim of this retrospective observational study is to determine if the method of detection of early breast cancer is predictive for additional positive nodes in patients with micrometastases in the SNs. METHODS: Between 2001 and 2011 a total of 1993 women with primary unilateral breast cancer had surgery at Skåne University Hospital, Lund. Of 1993 patients, 1458 had an SN biopsy and nearly all patients with micro- and macrometastases had ALND. RESULTS: Micrometastases defined as >0.2 mm/>200 cells and ≤2.0 mm were found in 62 of 757 screen-detected patients and in 81 of 701 patients with symptomatic breast cancer. Only 3 of the screen-detected patients with micrometastases, all with tumour size >15 mm (range 18-39 mm), had metastases in the completion ALND whereas this was found in 18 of the symptomatic patients with micrometastases (p = 0.01), (tumour size, range 10-30 mm). Logistic regression analysis adjusted for method of detection, tumour size and histological grade showed 5 times higher odds for further metastases in ALND in patients with symptomatic presentation vs. screen-detected breast cancer. CONCLUSION: Despite the small number of patients with micrometastases in this large cohort of breast cancer patients, these results support the contention that completion ALND can safely be omitted in screen-detected breast cancer patients with micrometastases in the SNs.


Subject(s)
Breast Neoplasms/pathology , Breast Neoplasms/surgery , Carcinoma, Ductal, Breast/secondary , Carcinoma, Ductal, Breast/surgery , Lymph Node Excision , Lymph Nodes/pathology , Lymph Nodes/surgery , Adult , Aged , Axilla , Biomarkers, Tumor/analysis , Breast Neoplasms/diagnostic imaging , Carcinoma, Lobular/secondary , Carcinoma, Lobular/surgery , Cohort Studies , Female , Humans , Logistic Models , Lymphatic Metastasis , Mammography , Mastectomy/methods , Middle Aged , Neoplasm Grading , Neoplasm Micrometastasis , Nomograms , Odds Ratio , Retrospective Studies , Sentinel Lymph Node Biopsy
12.
Br J Dermatol ; 168(4): 779-86, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23066913

ABSTRACT

BACKGROUND: Survival and prognostic factors for thin melanomas have been studied relatively little in population-based settings. This patient group accounts for the majority of melanomas diagnosed in western countries today, and better prognostic information is needed. OBJECTIVES: The aim of this study was to use established prognostic factors such as ulceration, tumour thickness and Clark's level of invasion for risk stratification of T1 cutaneous melanoma. METHODS: From 1990 to 2008, the Swedish Melanoma Register included 97% of all melanomas diagnosed in Sweden. Altogether, 13,026 patients with T1 melanomas in clinical stage I were used for estimating melanoma-specific 10- and 15-year mortality rates. The Cox regression model was used for further survival analysis on 11,165 patients with complete data. RESULTS: Ulceration, tumour thickness and Clark's level of invasion all showed significant, independent, long-term prognostic information. By combining these factors the patients could be subdivided into three risk groups: a low-risk group (67·9% of T1 cases) with a 10-year melanoma-specific mortality rate of 1·5% (1·2-1·9%); an intermediate-risk group (28·6% of T1 cases) with a 10-year mortality rate of 6·1% (5·0-7·3%); and a high-risk group (3·5% of T1 cases) with a 10-year mortality rate of 15·6% (11·2-21·4%). The high- and intermediate-risk groups accounted for 66% of melanoma deaths within T1. CONCLUSIONS: Using a population-based melanoma register, and combining ulceration, tumour thickness and Clark's level of invasion, three distinct prognostic subgroups were identified.


Subject(s)
Melanoma/mortality , Skin Neoplasms/mortality , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Humans , Infant , Male , Melanoma/pathology , Middle Aged , Neoplasm Invasiveness , Prognosis , Prospective Studies , Registries , Skin Neoplasms/pathology , Skin Ulcer/mortality , Skin Ulcer/pathology , Survival Rate , Sweden/epidemiology , Young Adult
13.
Br J Surg ; 99(2): 226-31, 2012 Feb.
Article in English | MEDLINE | ID: mdl-22180063

ABSTRACT

BACKGROUND: Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) as the standard axillary staging procedure in breast cancer. Follow-up studies in SLN-negative women treated without ALND report low rates of axillary recurrence, but most studies have short follow-up, and few are multicentre studies. METHODS: Between September 2000 and January 2004, patients who were SLN-negative and did not have ALND were included in a prospective cohort. Kaplan-Meier estimates were used to analyse the rates of axillary recurrence and survival. The risk of axillary recurrence was also compared in centres with high and low experience with the SLN biopsy (SLNB) technique. RESULTS: A total of 2195 patients with 2216 breast tumours were followed for a median of 65 months. Isolated axillary recurrence was diagnosed in 1·0 per cent of patients. The event-free 5-year survival rate was 88·8 per cent and the overall 5-year survival rate 93·1 per cent. There was no difference in recurrence rates between centres contributing fewer than 150 SLNB procedures to the cohort and centres contributing 150 or more procedures. CONCLUSION: This study confirmed the low risk of axillary recurrence 5 years after SLNB for breast cancer without ALND.


Subject(s)
Breast Neoplasms/pathology , Lymph Nodes/pathology , Neoplasm Recurrence, Local/pathology , Adult , Aged , Aged, 80 and over , Axilla , Breast Neoplasms/surgery , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Lymphatic Metastasis , Mammography , Middle Aged , Neoplasm Staging/methods , Physical Examination , Prospective Studies , Sentinel Lymph Node Biopsy , Treatment Outcome , Young Adult
14.
Br J Cancer ; 105(11): 1676-83, 2011 Nov 22.
Article in English | MEDLINE | ID: mdl-22033271

ABSTRACT

BACKGROUND: The androgen receptor (AR) is frequently expressed in breast cancers. The AR genotype may affect disease-free survival and response to endocrine therapy. METHODS: In all, 634 women undergoing breast cancer surgery between 2002 and 2008 were followed until 30 June 2010. Six haplotype-tagging single-nucleotide polymorphisms in the AR, and the resulting AR diplotypes, were examined in relation to breast cancer patient characteristics, tumour characteristics, disease-free survival, and response to endocrine treatment. RESULTS: Five common AR diplotypes were found. Seventeen rare variants were combined into a composite group. The resulting six AR diplotype groups were clustered into two subgroups, groups A (n=128) and B (n=499), with three diplotypes in each. Patients in group B had larger total breast volume (P=0.024), higher body mass index (BMI) (P=0.050), more axillary lymph node involvement (P(trend)=0.020), and higher histological grade (P(trend)=0.031). There were 59 breast cancer events in the 569 patients with invasive cancers and no preoperative treatment. Patients in group B also had shorter disease-free survival (P=0.037) than patients in group A. Among patients in group B with oestrogen receptor α positive tumours, tamoxifen (TAM) treatment was associated with longer disease-free survival (P=0.008), while treatment with aromatase inhibitors (AIs) was not (P=0.94). Response to endocrine treatment could not be predicted based on BMI, suggesting that the effect of AR diplotypes went beyond that of a higher BMI. CONCLUSION: A marker for a group of patients who responded to TAM, but not to AIs, was identified. If this finding is confirmed, AR genotyping may provide useful information for selection of endocrine treatment of breast cancer patients.


Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Aromatase Inhibitors/therapeutic use , Biomarkers, Tumor/genetics , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Receptors, Androgen/genetics , Aged , Base Sequence , Breast Neoplasms/pathology , Breast Neoplasms/surgery , Disease-Free Survival , Female , Genetic Testing , Haplotypes , Humans , Middle Aged , Neoplasms, Hormone-Dependent/drug therapy , Neoplasms, Hormone-Dependent/genetics , Neoplasms, Hormone-Dependent/pathology , Neoplasms, Hormone-Dependent/surgery , Polymorphism, Single Nucleotide , Tamoxifen/therapeutic use
15.
Int J Mol Imaging ; 2011: 828151, 2011.
Article in English | MEDLINE | ID: mdl-21603241

ABSTRACT

Aim. To develop a method and obtain proof-of-principle for immunolymphoscintigraphy for identification of metastatic sentinel nodes. Methods. We selected one of four tumour-specific antibodies against human breast cancer and investigated (1), in immune-deficient (nude) mice with xenograft human breast cancer expressing the antigen if specific binding of the intratumorally injected, radioactively labelled, monoclonal antibody could be scintigraphically visualized, and (2) transportation to and retention in regional lymph nodes of the radioactively labelled antibody after subcutaneous injection in healthy rabbits. Results and Conclusion. Our paper suggests the theoretical possibility of a model of dual isotope immuno-lymphoscintigraphy for noninvasive, preoperative, malignant sentinel node imaging.

16.
J Natl Cancer Inst ; 102(20): 1568-83, 2010 Oct 20.
Article in English | MEDLINE | ID: mdl-20876876

ABSTRACT

BACKGROUND: Carrying the cyclin-dependent kinase inhibitor 2A (CDKN2A) germline mutations is associated with a high risk for melanoma. Penetrance of CDKN2A mutations is modified by pigmentation characteristics, nevus phenotypes, and some variants of the melanocortin-1 receptor gene (MC1R), which is known to have a role in the pigmentation process. However, investigation of the associations of both MC1R variants and host phenotypes with melanoma risk has been limited. METHODS: We included 815 CDKN2A mutation carriers (473 affected, and 342 unaffected, with melanoma) from 186 families from 15 centers in Europe, North America, and Australia who participated in the Melanoma Genetics Consortium. In this family-based study, we assessed the associations of the four most frequent MC1R variants (V60L, V92M, R151C, and R160W) and the number of variants (1, ≥2 variants), alone or jointly with the host phenotypes (hair color, propensity to sunburn, and number of nevi), with melanoma risk in CDKN2A mutation carriers. These associations were estimated and tested using generalized estimating equations. All statistical tests were two-sided. RESULTS: Carrying any one of the four most frequent MC1R variants (V60L, V92M, R151C, R160W) in CDKN2A mutation carriers was associated with a statistically significantly increased risk for melanoma across all continents (1.24 × 10(-6) ≤ P ≤ .0007). A consistent pattern of increase in melanoma risk was also associated with increase in number of MC1R variants. The risk of melanoma associated with at least two MC1R variants was 2.6-fold higher than the risk associated with only one variant (odds ratio = 5.83 [95% confidence interval = 3.60 to 9.46] vs 2.25 [95% confidence interval = 1.44 to 3.52]; P(trend) = 1.86 × 10(-8)). The joint analysis of MC1R variants and host phenotypes showed statistically significant associations of melanoma risk, together with MC1R variants (.0001 ≤ P ≤ .04), hair color (.006 ≤ P ≤ .06), and number of nevi (6.9 × 10(-6) ≤ P ≤ .02). CONCLUSION: Results show that MC1R variants, hair color, and number of nevi were jointly associated with melanoma risk in CDKN2A mutation carriers. This joint association may have important consequences for risk assessments in familial settings.


Subject(s)
Genes, p16 , Heterozygote , Melanoma/genetics , Mutation , Receptor, Melanocortin, Type 1/genetics , Skin Neoplasms/genetics , Adult , Australia , Cyclin-Dependent Kinase Inhibitor p16/genetics , Europe , Female , Hair Color , Humans , Male , Nevus/complications , Nevus/genetics , North America , Phenotype , Risk Assessment , Risk Factors , Skin Pigmentation , Sunburn/complications , White People/genetics
17.
Br J Cancer ; 101(11): 1817-23, 2009 Dec 01.
Article in English | MEDLINE | ID: mdl-19935798

ABSTRACT

BACKGROUND: CYP2C8/9 polymorphisms may influence breast cancer-free survival after diagnosis due to their role in the metabolism of tamoxifen, paclitaxel, and other chemotherapy. cytochrome P450 (CYP)2C8/9 metabolise arachidonic acid to epoxyeicosatrienoic acids, which enhance migration and invasion in vitro and promote angiogenesis in vivo. We aimed to investigate the frequency of CYP2C8/9 polymorphisms in relation to breast tumour characteristics and disease-free survival. METHODS: A prospective series of 652 breast cancer patients from southern Sweden was genotyped for CYP2C8*3, CYP2C8*4, CYP2C9*2, and CYP2C9*3. Blood samples and questionnaires were obtained pre- and postoperatively. Clinical information and tumour characteristics were obtained from patients' charts and pathology reports. RESULTS: Frequencies of CYP2C8/9 polymorphisms were similar to healthy European populations. Significantly less node involvement (P=0.002) and fewer PR+ tumours (P=0.012) were associated with CYP2C8*4. Median follow-up was 25 months and 52 breast cancer-related events were reported. In a multivariate model, CYP2C8/9*3/*1*/*2/*1 was the only factor associated with increased risk for early events in 297 tamoxifen-treated, ER-positive patients, adjusted HR 2.54 (95%CI 1.11-5.79). The effect appeared to be driven by CYP2C8*3, adjusted HR 8.56 (95%CI 1.53-51.1). CONCLUSION: Polymorphic variants of CYP2C8/9 may influence breast tumour characteristics and disease-free survival in tamoxifen-treated patients.


Subject(s)
Aryl Hydrocarbon Hydroxylases/genetics , Breast Neoplasms/enzymology , Aged , Antineoplastic Agents, Hormonal/therapeutic use , Aryl Hydrocarbon Hydroxylases/metabolism , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Breast Neoplasms/pathology , Cytochrome P-450 CYP2C8 , Cytochrome P-450 CYP2C9 , Disease-Free Survival , Female , Haplotypes , Humans , Immunohistochemistry , Middle Aged , Neoadjuvant Therapy , Polymorphism, Genetic , Prognosis , Prospective Studies , Survival Analysis , Tamoxifen/therapeutic use
18.
Eur J Surg Oncol ; 34(7): 739-45, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18291614

ABSTRACT

AIM: To find out if ILT can be used as radical treatment of breast cancer. METHOD: Twenty-four patients, aged 39-84 (mean 61), with invasive breast cancer were treated with ILT. All underwent mammography, ultrasound and core biopsy before treatment. The tumour was an invasive ductal carcinoma in 15 patients, a lobular carcinoma in eight and lobular-ductal cancer in one. Average tumour diameter was 14 mm on ultrasound (5-35). Patients were treated in the outpatient clinics under local anaesthesia. Probes were placed under ultrasound guidance, in 19 patients, and ILT was performed with a diode laser at a steady-state temperature of 48 degrees C for 30 min using temperature feedback control. Standard surgical excision was performed 12 (4-23) days after ILT and was preceded by Doppler ultrasound. RESULTS: Treatment-induced necrosis of invasive cancer was 33% (range 0-100) and was complete in three patients. At follow-up before surgery, the extent of laser damage could not be judged with ultrasound, although abolished tumour blood flow was demonstrated after treatment resulting in large necroses. Efficacy of treatment varied negatively with tumour size. The inefficacy of ILT was mainly due to the underestimation of tumour size by mammography and ultrasound and the shortcomings of these methods to demonstrate tumour borders, tumour irregularity and carcinoma in situ (CIS). ILT was well tolerated. Five patients had breast tenderness, and three patients had pain, during the first day after treatment. Small skin necroses were observed in two patients. CONCLUSION: Small breast cancers can be treated radically with ILT. The method may become useful in the treatment of breast cancer but needs further refinement, even for small well-defined breast cancers, if it is going to be employed for radical treatment.


Subject(s)
Breast Neoplasms/therapy , Hyperthermia, Induced/methods , Laser Therapy/methods , Adult , Aged , Aged, 80 and over , Breast Neoplasms/pathology , Female , Humans , Hyperthermia, Induced/adverse effects , Laser Therapy/adverse effects , Middle Aged , Pilot Projects , Ultrasonography, Interventional
20.
Br J Surg ; 94(8): 948-51, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17436338

ABSTRACT

BACKGROUND: Sentinel node biopsy (SNB) is a standard staging procedure in early breast cancer. Its suitability for larger tumours has been questioned. This study evaluated the reliability of SNB in women with invasive breast cancer larger than 3 cm in diameter who were clinically axillary node negative. METHODS: Some 109 women with a tumour larger than 3 cm on pathological analysis were identified from the Swedish prospective SNB database. They were included if a completion axillary clearance was planned, regardless of SNB results. RESULTS: The sentinel node detection rate was 103 (94.5 per cent) of 109. The overall false-negative rate was eight (13 per cent) of 64. Although a preoperative diagnosis of multifocal tumour was an exclusion criterion, 16 such cases were revealed on postoperative pathological examination. The false-negative rate in this subgroup was higher than that in women with a unifocal tumour (four (31 per cent) of 13 versus four (8 per cent) of 51; P = 0.012). No other significant predictors of a false-negative sentinel node biopsy were identified. CONCLUSION: SNB is feasible in patients with unifocal breast tumours larger than 3 cm. When large tumour size coincides with multifocality, however, the false-negative rate seems to be increased and a completion axillary clearance should be considered even if the SNB is negative.


Subject(s)
Breast Neoplasms/pathology , Breast/pathology , Sentinel Lymph Node Biopsy , Adult , Aged , Aged, 80 and over , Breast Neoplasms/surgery , False Positive Reactions , Feasibility Studies , Female , Humans , Lymphatic Metastasis , Mastectomy, Segmental/methods , Middle Aged , Neoplasm Staging/methods , Prospective Studies , Regression Analysis , Sentinel Lymph Node Biopsy/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...